Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: Effects of apolipoproteins

Current Opinion in Lipidology

Volumn 18, Issue 3, 2007, Pages 251-257

  Dallinga Thie, Geesje M ^a   Dullaart, Robin P F ^b   Van Tol, Arie ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apolipoprotein A I; Apolipoprotein E; Cholesteryl ester transfer protein; Phospholipid transfer protein; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HUMAN; LIPOPROTEIN METABOLISM; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

AGED; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS E; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; MODELS, BIOLOGICAL; PHOSPHOLIPID TRANSFER PROTEINS; VITAMIN E;

EID: 34248380100     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3280e12685     Document Type: Review

References (87)

1. Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333-1346.
2. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease - a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100:1134-1146.
3. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Ann Rev Nutr 1998; 18:297-330.
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46:733-749.
5. Guerin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21:282-288.
6. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Rev 2002; 23:201-229.
7. Adiels M, Boren J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25:1697-1703.
8. Chetiveaux M, Lalanne F, Lambert G, et al. Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients. Eur J Clin Invest 2006; 36:29-34. A stable isotope study showing increased fractional clearance rates of both large and small HDL subfractions in type 2 diabetes.
9. Marcel YL, McPherson R, Hogue M, et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipidemic subjects. J Clin Invest 1990; 85:10-17.
10. Clark RW, Moberly JB, Bamberger MJ. Low level quantification of cholesteryl ester transfer protein in plasma subfractions and cell culture media by monoclonal antibody-based immunoassay. J Lipid Res 1995; 36:876-889.
11. De Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005; 54:3554-3559.
12. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006; 47:537-552. This paper provides an excellent overview on the function of CETP and the putative working mechanism of the CETP inhibitor torcetrapib.
13. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43:1363-1379.
14. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21:13-27.
15. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160-167.
16. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58:342-374. This review provides a comprehensive summary on currently known aspects of HDL function and metabolism.
17. Borggreve SE, De Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003; 33:1051-1069.
18. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004; 45:1594-1607.
19. Radeau T, Lau P, Robb M, et al. Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J Lipid Res 1995; 36:2552-2561.
20. Arai T, Yamashita S, Hirano K, et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994; 14:1129-1136.
21. Dullaart RPF, Sluiter WJ, Dikkeschei LD, et al. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994; 24:188-194.
22. Jiang XC, Zhou HW. Plasma lipid transfer proteins. Curr Opin Lipidol 2006; 17:302-308.
23. Zhou H, Li Z, Hojjati MR, et al. Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism. J Lipid Res 2006; 47:2011-2019.
24. Gauthier A, Lau P, Zha X, et al. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005; 25:2177-2184.
25. Zhou H, Li Z, Silver DL, Jiang XC. Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor. Biochim Biophys Acta 2006; 1761:1482-1488. This study in CETP transgenic mice with hepatic scavenger receptor B1 deficiency provides evidence for a function of CETP beyond its well-known lipid transfer capacity.
26. Guerin M, Le Goff W, Lassel TS, et al. Proatherogenic role of elevated cholesteryl ester transfer from HDL to VLDL1 and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21:282-288.
27. Bhatnagar D, Durrington PN, Kumar S, et al. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with noninsulin-dependent diabetes mellitus. Diabet Med 1995; 13:139-144.
28. Riemens S, van Tol A, Sluiter W, Dullaart RPF. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998; 140:71-79.
29. Van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003; 26:1216-1223.
30. Niemeijer-Kanters SD, Dallinga-Thie GM, Ruijter-Heijstek FC, et al. Effect of intensive lipid lowering strategy on low density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis 2001; 156:209-216.
31. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and Nutrition) - Norfolk population study. Circulation 2004; 110:1418-1423.
32. Rye KA, Wee K, Curtiss LK, et al. Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. J Biol Chem 2003; 278:22530-22536.
33. Liang HQ, Rye KA, Barter PJ. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res 1994; 35:1187-1199.
34. Rye KA, Hime NJ, Barter PJ. The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J Biol Chem 1995; 270:189-196.
35. Cohn JS, Batal R, Tremblay M, et al. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J Lipid Res 2003; 44:1976-1983.
36. Rye KA, Bright R, Psaltis M, Barter PJ. Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. J Lipid Res 2006; 47:1025-1036.
37. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31:445-454. This comprehensive review adds to our current understanding of the structural properties of apolipoprotein E in determining its pathophysiological role.
38. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoC-I-knocked out mice. J Biol Chem 2002; 277:31354-31363.
39. Gautier T, Masson D, de Barros JP, et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem 2000; 275:37504-37509.
40. Dumont L, Gautier T, de Barros JP, et al. Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem 2005; 280:38108-38116.
41. Gautier T, Masson D, Jong MC, et al. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. Biochem J 2005; 385:189-195.
42. Morton RE, Greene DJ. Enhanced detection of lipid transfer inhibitor protein activity by an assay involving only low density lipoprotein. J Lipid Res 1994; 35:2094-2099.
43. Paromov VM, Morton RE. Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J Biol Chem 2003; 278:40859-40866.
44. Main LA, Ohnishi T, Yokoyama S. Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV. Biochim Biophys Acta 1996; 1300:17-24.
45. Verges BL, Lagrost L, Vaillant G, et al. Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM. Diabetes 1997; 46:125-132.
46. Van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002; 13:135-139.
47. Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol 2004; 15:255-260.
48. Oka T, Kujiraoka T, Ito M, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 2000; 41:1651-1657.
49. Oka T, Kujiraoka T, Ito M, et al. Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin Chem 2000; 46:1357-1364.
50. Karkkainen M, Oka T, Olkkonen VM, et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 2002; 277:15413-15418.
51. Murdoch SJ, Wolfbauer G, Kennedy H, et al. Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res 2002; 43:281-289.
52. Desrumaux C, Athias A, Bessède G, et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and noninsulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999; 19:266-275.
53. Siggins S, Karkkainen M, Tenhunen J, et al. Quantitation of the active and lowactive forms of human plasma phospholipid transfer protein by ELISA. J Lipid Res 2004; 45:387-395.
54. Rye KA, Barter PJ. Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor. Biochim Biophys Acta 1986; 875:429-438.
55. Jauhiainen M, Metso J, Pahlman R, et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993; 268:4032-4036.
56. Settasatian N, Duong MN, Curtiss LK, et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 2001; 276:26898-26905.
57. Von Eckardstein A, Jauhiainen M, Huang YD, et al. Phospholipid transfer protein mediated conversion of high density lipoproteins generates beta1-HDL. Biochim Biophys Acta 1996; 1301:255-262.
58. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 2006; 26:12-19. This review summarizes the many possible roles of apolipoprotein A-I in reverse cholesterol transport from macrophages as well as the putative functions of PLTP and CETP.
59. Van Haperen R, Van Tol A, Van Gent T, et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 2002; 277:48938-48943.
60. Jiang XC, Qin SC, Qiao CP, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7:849-854.
61. Lie J, De Crom R, van Gent T, et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J Lipid Res 2002; 43:1875-1880.
62. Jiang XC, Li Z, Liu R, et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem 2005; 280:18336-18340.
63. Desrumaux CM, Mak PA, Boisvert WA, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003; 44:1453-1461.
64. O'Brien KD, Vuletic S, McDonald TO, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 2003; 108:270-274.
65. Valenta DT, Ogier N, Bradshaw G, et al. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol 2006; 26:1572-1578.
66. Liu R, Hojjati MR, Devlin CM, et al. Macrophage phospholipid transfer protein deficiency and apoe secretion. Impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 27:190-196.
67. -/--recipient mice, the authors show that PLTP deficiency in macrophages leads to a decrease in the atherosclerotic lesion area, which is in favour of an atherogenic function of PLTP.
68. Van Haperen R, Samyn H, Moerland M, et al. Elevated macrophage expression of phospholipid transfer protein causes atherosclerosis [Abstract no. 1199]. Circulation 2006; 114(Suppl. II-225).
69. Riemens SC, van Tol A, Sluiter WJ, Dullaart RPF. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998; 41:929-934.
70. Jonkers IJ, Smelt AH, Hattori H, et al. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 2003; 44:1462-1469.
71. Tan KC, Shiu SW, Wong Y, Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005; 178:365-370.
72. Kaser S, Sandhofer A, Foger B, et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001; 44:1111-1117.
73. Murdoch SJ, Carr MC, Hokanson JE, et al. PLTP activity in premenopausal women: relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res 2000; 41:237-244.
74. Cheung MC, Knopp RH, Retzlaff B, et al. Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim Biophys Acta 2002; 1587:53-59.
75. Barlage S, Frohlich D, Bottcher A, et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001; 42:281-290.
76. Dullaart RPF, de Vries R, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 2007; 1771:113-118.
77. Colhoun HM, Taskinen MR, Otvos JD, et al. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002; 51:3300-3305.
78. De Vries R, Kerstens MN, Sluiter WJ, et al. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005; 48:1105-1113.
79. Dallinga-Thie GM, van Tol A, Hattori H, et al. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes 2006; 55:1491-1496. This intervention study illustrates the relationship between apolipoprotein E and PLTP activity in type 2 diabetes. The decrease in apolipoprotein E was the only determinant for the decrease in PLTP activity during high-dose statin treatment.
80. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23:1857-1862.
81. De Vries R, Dallinga-Thie GM, Smit AJ, et al. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006; 49:398-404. This study shows that PLTP activity is elevated in type 2 diabetes and that it is a determinant of intima-media thickness, a surrogate marker of atherosclerosis.
82. Janis MT, Siggins S, Tahvanainen E, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res 2004; 45:2303-2309.
83. Siggins S, Jauhiainen M, Olkkonen VM, et al. PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res 2003; 44:1698-1704.
84. Janis MT, Metso J, Lankinen H, et al. Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 2005; 331:333-340.
85. Tan KC, Shiu SW, Wong Y, et al. Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus. Diabet Metab Res Rev 2006; 22:307-312.
86. Cheung MC, Albers JJ. Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins. J Lipid Res 2006; 47:1315-1321.
87. Tall AR, Yvan-Charvat L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007; 27:257-260.